Emma Andrus, Associate Editor

ENS-002 targets S. aureus in atopic dermatitis.

2-year data show 75.7% of TNFi-IR patients maintained ACR50, 80.6% achieved PASI100, and pain and fatigue improvements were sustained.

The ILDS has named 6 young dermatologists from around the world as recipients of the 2025 Young Dermatologists International Achievement Awards for their contributions to dermatology.

In a Dermatology Times Case-Based Peer Perspective event, Terry Faleye, MPAS, PA-C, reviewed 2 cases of patients with vitiligo to discuss innovative treatments and emotional challenges with disease management.

A study showed NB-UVB phototherapy effectively reduced prurigo nodularis symptoms, with 80% of patients achieving full response.

RAD will join MJH's multichannel model, enhancing its educational impact in atopic dermatitis, alopecia areata, vitiligo, and eczema.

Abeona's pz-cel has been granted a April 29, 2025, PDUFA date.

Catch up on coverage from the 2024 Elevate-Derm West Conference in Scottsdale, Arizona.

Catch up on coverage from the fourth and final day of the 2024 Elevate-Derm West Conference in Scottsdale, Arizona.

Discover top innovations, insights, and clinical pearls from Elevate-Derm in Scottsdale, where top insights for advanced practice providers took center stage.

At Elevate-Derm West, Murase shared promising results in treating severe itch with emerging therapies, offering hope for patients with few options.

Swanson shared practical tips from her Elevate-Derm West sessions, empowering clinicians with new strategies for pediatric skin care.

Marghoob shares key dermoscopic features to help clinicians identify benign vs malignant lesions on various locations of the body.

Catch up on coverage from the third day of the 2024 Elevate-Derm West Conference in Scottsdale, Arizona.

Delgocitinib cream offers a safe, low-systemic-exposure option for chronic hand eczema, according to a poster from the Elevate-Derm conference.

The TRACE study showed tralokinumab reduced genital AD severity and improved quality of life within 3 months of treatment.

Catch up on coverage from the second day of the 2024 Elevate-Derm West Conference in Scottsdale, Arizona.

Expert tips from Whitney High, MD, at Elevate-Derm West 2024 guide experienced advanced practice providers in mastering dermatopathology and avoiding diagnostic pitfalls.

A poster presented at the 2024 Elevate-Derm West Conference outlines the pharmacokinetic profiles of spesolimab via intravenous and subcutaneous administration.

Catch up on coverage from the first day of the 2024 Elevate-Derm West Conference in Scottsdale, Arizona.

Roflumilast foam 0.3% significantly improved psoriasis severity, symptoms, and quality of life in patients with moderate to severe scalp and body psoriasis.

Apremilast led to a 75% improvement in PPPASI-75 in a significant portion of patients by week 16, with these improvements maintained through week 52.

The conference aimed at providing dermatology NPs and PAs with the latest in the specialty begins today in Scottsdale, Arizona.

We want to know: Will you be attending the conference in Scottsdale later this week?

The target action review date has been pushed to March 12, 2025.

Dermatology Times asked our readers to share what conferences they are looking forward to in the fourth quarter of 2024.

Dermatology Times is looking back on the top stories in dermatology from the month of October.

Dermatology Times is recapping our top expert interviews from the month of October.

Catch up on coverage from the 2024 Fall Clinical Dermatology Conference in Las Vegas, Nevada.

In a Dermatology Times Case-Based Roundtable event, Pearl E. Grimes, MD, FAAD, reviewed 2 cases of patients with vitiligo treated with ruxolitinib.